Harvard Bioscience Inc
HBIO· Nasdaq
HBIOHarvard Bioscience Inc
Released Aug 8, 2024, before the open
10-Q filed Aug 8, 2024, 39 days after period end · 0001171843-24-004564
| Metric | Q2 2024 | Q2 2023 | Q2 2022 | Q2 2021 |
|---|---|---|---|---|
| Revenue | $23.10M | $28.76M | $29.21M | $29.20M |
| Net Income | -$2.93M | -$980.00K | $2.44M | -$410.00K |
| EPS Diluted |
Harvard Bioscience Inc · CIK 1123494 · Engraved from SEC EDGAR
| -$0.07 |
| -$0.02 |
| $0.06 |
| -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
